还没做过化疗，EGFR是野生型的病友一定要去做ALK的检测

jzjqian 发表于 2012-7-25 15:45

                               
登录/注册后可看大图

, [) E! Z0 L$ r' I9 a7 F) q! f请教，像我这样的，手术22个月了，还能去原手术医院拿到病理作EGFR检查么？

可以，但要有针对性，

请问，肺鳞癌，只做过一次化疗，骨髓抑制严重，后吃特罗凯4个月基本无效，可以参加实验组吗？

不可以了,要没做过任何治疗的,包括化疗和靶向药

Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  


+ l8 n7 X  V- \7 k& y5 jSub-category:
Molecular Targets


Category:
Tumor Biology


2 x/ \+ k: U+ ~' A) R' sMeeting:
2011 ASCO Annual Meeting
$ y0 S$ u' _" t) [$ w; Z( X
& F0 d1 @- Z( q1 G& B; o$ c2 C# Q
Session Type and Session Title:
# u6 L  p, H$ i) hPoster Discussion Session, Tumor Biology
  C1 O- y" J; g9 Q
* A, X) ^1 u: k& E; h; j0 a( r8 b
Abstract No:
10517


& A% y2 E% |' Y6 S6 PCitation:
J Clin Oncol 29: 2011 (suppl; abstr 10517)


Author(s):
: K4 l# u; A: Y" M/ z+ z2 zJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
6 g$ L$ V, ~- u/ [$ s
0 }- Z8 @/ \! t& ^$ Z
) |2 P, [. }# v* A- H
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
& Z3 R. D7 u6 R" Q3 [
Abstract Disclosures

Abstract:
3 ?( |  k- a8 }

Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
2 \( W5 ~5 U# v

  M. f" R* C& _6 L* L4 p* D

由吴一龙教授牵头的A80810029临床试验上周启动，初诊未治疗的晚期肺腺癌患者检测到ALK阳性，可参加一线crizotinib 对比力比泰+卡铂的临床研究，药物全部免费，即使分配到力比泰组，疾病进展之后可免费获得crizotinib.

没有手术，只化疗过，现吃靶向药，未突变，alk未测，有机会入组吗？

boeun 发表于 2012-11-18 16:37

                               
登录/注册后可看大图

/ {0 Z4 w- R0 ^* e1 P没有手术，只化疗过，现吃靶向药，未突变，alk未测，有机会入组吗？

" d7 H2 h' S  n/ i* e3 j化疗过的没机会了

平安！ 发表于 2012-7-20 11:20

                               
登录/注册后可看大图

易瑞沙、特罗凯有效的病人基本上可以断定ALK（-）。极其罕见EGFR、ALK同时突变的。
  t' }1 ]. a  e4 g5 K1 a8 j8 VALK一个指标医院要900多 ...

4 A# y; {% s; G7 H* \+ s3 S3 D1 f平安，真的没有希望吗？我弟弟虽然特罗凯有效，但是ＥＧＦＲ是野生型，不是突变啊。有没有必要去检测ＡＬＫ呢？
2 t7 b4 M; C7 e% t# m
- d0 F% a0 y0 y5 Y, D/ w现在病情进展，快没招儿了。

好像想加入挺困难的

小地方没条件做啊